IP Library › Granted Patent US 8,940,710

Granted Patent B2

US 8,940,710 · App. 13/836,907 · Granted Jan 27, 2015

Human monoclonal antibody

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 8,940,710
App. No.: 13/836,907
Granted: Jan 27, 2015
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention provides an anti-CD81 antibody usable as a pharmaceutical product for human. Specifically, the present invention provides an anti-human CD81 antibody capable of binding to a peptide region consisting of the amino acid sequence of the amino acid numbers 80 to 175 in the amino acid sequence shown in SEQ ID NO:22.

Claims (534)

1. An isolated polynucleotide comprising a nucleotide sequence that encodes a heavy chain variable region and a light chain variable region of an isolated anti-human CD81 antibody capable of binding to a peptide region consisting of the amino acid sequence of the amino acid numbers 80 to 175 in the amino acid sequence of SEQ ID NO: 22.

2. A combination of an isolated polynucleotide comprising a nucleotide sequence that encodes a heavy chain variable region of an isolated anti-human CD81 antibody, and an isolated polynucleotide comprising a nucleotide sequence that encodes the corresponding light chain variable region of the anti-human CD81 antibody, wherein the anti-human CD81 antibody comprises all 6 complementarity determining regions (CDRs) described in any one of the following groups 1 to 24:

Group 1

(a-1) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-1) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-1) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-1) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-1) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-1) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 2

(a-2) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-2) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-2) a CDR comprising the amino acid sequence of SEQ ID NO: 37,

(d-2) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-2) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-2) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 3

(a-3) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-3) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-3) a CDR comprising the amino acid sequence of SEQ ID NO: 40,

(d-3) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-3) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-3) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 4

(a-4) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-4) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-4) a CDR comprising the amino acid sequence of SEQ ID NO: 43,

(d-4) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-4) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-4) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 5

(a-5) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-5) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-5) a CDR comprising the amino acid sequence of SEQ ID NO: 46,

(d-5) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-5) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-5) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 6

(a-6) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-6) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-6) a CDR comprising the amino acid sequence of SEQ ID NO: 49,

(d-6) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-6) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-6) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 7

(a-7) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-7) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-7) a CDR comprising the amino acid sequence of SEQ ID NO: 52,

(d-7) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-7) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-7) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 8

(a-8) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-8) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-8) a CDR comprising the amino acid sequence of SEQ ID NO: 43,

(d-8) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-8) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-8) a CDR comprising the amino acid sequence of SEQ ID NO: 55

Group 9

(a-9) a CDR comprising the amino acid sequence of SEQ ID NO: 60,

(b-9) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-9) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-9) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-9) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-9) a CDR comprising the amino acid sequence of SEQ ID NO: 61

Group 10

(a-10) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-10) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-10) a CDR comprising the amino acid sequence of SEQ ID NO: 66,

(d-10) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-10) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-10) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 11

(a-11) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-11) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-11) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-11) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-11) a CDR comprising the amino acid sequence of SEQ ID NO: 69, and

(f-11) a CDR comprising the amino acid sequence of SEQ ID NO: 70

Group 12

(a-12) a CDR comprising the amino acid sequence of SEQ ID NO: 60,

(b-12) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-12) a CDR comprising the amino acid sequence of SEQ ID NO: 66,

(d-12) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-12) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-12) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 13

(a-13) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-13) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-13) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-13) a CDR comprising the amino acid sequence of SEQ ID NO: 77,

(e-13) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-13) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 14

(a-14) a CDR comprising the amino acid sequence of SEQ ID NO: 80,

(b-14) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-14) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-14) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-14) a CDR comprising the amino acid sequence of SEQ ID NO: 81, and

(f-14) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 15

(a-15) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-15) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-15) a CDR comprising the amino acid sequence of SEQ ID NO: 66,

(d-15) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-15) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-15) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 16

(a-16) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-16) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-16) a CDR comprising the amino acid sequence of SEQ ID NO: 90,

(d-16) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-16) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-16) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 17

(a-17) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-17) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-17) a CDR comprising the amino acid sequence of SEQ ID NO: 52,

(d-17) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-17) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-17) a CDR comprising the amino acid sequence of SEQ ID NO: 93

Group 18

(a-18) a CDR comprising the amino acid sequence of SEQ ID NO: 98,

(b-18) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-18) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-18) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-18) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-18) a CDR comprising the amino acid sequence of SEQ ID NO: 99

Group 19

(a-19) a CDR comprising the amino acid sequence of SEQ ID NO: 60,

(b-19) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-19) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-19) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-19) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-19) a CDR comprising the amino acid sequence of SEQ ID NO: 99

Group 20

(a-20) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-20) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-20) a CDR comprising the amino acid sequence of SEQ ID NO: 90,

(d-20) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-20) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-20) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 21

(a-21) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-21) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-21) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-21) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-21) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-21) a CDR comprising the amino acid sequence of SEQ ID NO: 55

Group 22

(a-22) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-22) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-22) a CDR comprising the amino acid sequence of SEQ ID NO: 66,

(d-22) a CDR comprising the amino acid sequence of SEQ ID NO: 110,

(e-22) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-22) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 23

(a-23) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-23) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-23) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-23) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-23) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-23) a CDR comprising the amino acid sequence of SEQ ID NO: 115

Group 24

(a-24) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-24) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-24) a CDR comprising the amino acid sequence of SEQ ID NO: 90,

(d-24) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-24) a CDR comprising the amino acid sequence of SEQ ID NO: 120, and

(f-24) a CDR comprising the amino acid sequence of SEQ ID NO: 6.

3. A combination of an isolated polynucleotide comprising a nucleotide sequence that encodes a heavy chain variable region of an isolated anti-human CD81 antibody, and an isolated polynucleotide comprising a nucleotide sequence that encodes the corresponding light chain variable region of the isolated anti-human CD81 antibody, wherein the isolated anti-human CD81 antibody comprises:

(a-25) a CDR comprising the amino acid sequence of SEQ ID NO: 11;

(b-25) a CDR comprising the amino acid sequence of SEQ ID NO: 12;

(c-25) a CDR comprising the amino acid sequence of SEQ ID NO: 13;

(d-25) a CDR comprising the amino acid sequence of SEQ ID NO: 14;

(e-25) a CDR comprising the amino acid sequence of SEQ ID NO: 15; and

(f-25) a CDR comprising the amino acid sequence of SEQ ID NO: 16.

4. An isolated polynucleotide comprising a nucleotide sequence that encodes a heavy chain and a light chain of an isolated anti-human CD81 antibody capable of binding to a peptide region consisting of the amino acid sequence of the amino acid numbers 80 to 175 in the amino acid sequence of SEQ ID NO: 22.

5. A combination of an isolated polynucleotide comprising a nucleotide sequence that encodes a heavy chain of an isolated anti-human CD81 antibody, and an isolated polynucleotide comprising a nucleotide sequence that encodes the corresponding light chain of the anti-human CD81 antibody, wherein the anti-human CD81 antibody comprises all 6 complementarity determining regions (CDRs) described in any one of the following groups 1 to 24:

Group 1

(a-1) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-1) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-1) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-1) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-1) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-1) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 2

(a-2) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-2) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-2) a CDR comprising the amino acid sequence of SEQ ID NO: 37,

(d-2) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-2) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-2) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 3

(a-3) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-3) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-3) a CDR comprising the amino acid sequence of SEQ ID NO: 40,

(d-3) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-3) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-3) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 4

(a-4) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-4) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-4) a CDR comprising the amino acid sequence of SEQ ID NO: 43,

(d-4) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-4) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-4) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 5

(a-5) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-5) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-5) a CDR comprising the amino acid sequence of SEQ ID NO: 46,

(d-5) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-5) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-5) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 6

(a-6) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-6) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-6) a CDR comprising the amino acid sequence of SEQ ID NO: 49,

(d-6) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-6) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-6) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 7

(a-7) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-7) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-7) a CDR comprising the amino acid sequence of SEQ ID NO: 52,

(d-7) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-7) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-7) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 8

(a-8) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-8) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-8) a CDR comprising the amino acid sequence of SEQ ID NO: 43,

(d-8) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-8) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-8) a CDR comprising the amino acid sequence of SEQ ID NO: 55

Group 9

(a-9) a CDR comprising the amino acid sequence of SEQ ID NO: 60,

(b-9) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-9) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-9) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-9) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-9) a CDR comprising the amino acid sequence of SEQ ID NO: 61

Group 10

(a-10) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-10) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-10) a CDR comprising the amino acid sequence of SEQ ID NO: 66,

(d-10) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-10) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-10) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 11

(a-11) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-11) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-11) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-11) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-11) a CDR comprising the amino acid sequence of SEQ ID NO: 69, and

(f-11) a CDR comprising the amino acid sequence of SEQ ID NO: 70

Group 12

(a-12) a CDR comprising the amino acid sequence of SEQ ID NO: 60,

(b-12) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-12) a CDR comprising the amino acid sequence of SEQ ID NO: 66,

(d-12) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-12) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-12) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 13

(a-13) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-13) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-13) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-13) a CDR comprising the amino acid sequence of SEQ ID NO: 77,

(e-13) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-13) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 14

(a-14) a CDR comprising the amino acid sequence of SEQ ID NO: 80,

(b-14) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-14) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-14) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-14) a CDR comprising the amino acid sequence of SEQ ID NO: 81, and

(f-14) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 15

(a-15) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-15) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-15) a CDR comprising the amino acid sequence of SEQ ID NO: 66,

(d-15) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-15) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-15) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 16

(a-16) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-16) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-16) a CDR comprising the amino acid sequence of SEQ ID NO: 90,

(d-16) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-16) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-16) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 17

(a-17) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-17) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-17) a CDR comprising the amino acid sequence of SEQ ID NO: 52,

(d-17) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-17) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-17) a CDR comprising the amino acid sequence of SEQ ID NO: 93

Group 18

(a-18) a CDR comprising the amino acid sequence of SEQ ID NO: 98,

(b-18) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-18) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-18) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-18) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-18) a CDR comprising the amino acid sequence of SEQ ID NO: 99

Group 19

(a-19) a CDR comprising the amino acid sequence of SEQ ID NO: 60,

(b-19) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-19) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-19) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-19) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-19) a CDR comprising the amino acid sequence of SEQ ID NO: 99

Group 20

(a-20) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-20) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-20) a CDR comprising the amino acid sequence of SEQ ID NO: 90,

(d-20) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-20) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-20) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 21

(a-21) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-21) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-21) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-21) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-21) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-21) a CDR comprising the amino acid sequence of SEQ ID NO: 55

Group 22

(a-22) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-22) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-22) a CDR comprising the amino acid sequence of SEQ ID NO: 66,

(d-22) a CDR comprising the amino acid sequence of SEQ ID NO: 110,

(e-22) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-22) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 23

(a-23) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-23) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-23) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-23) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-23) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-23) a CDR comprising the amino acid sequence of SEQ ID NO: 115

Group 24

(a-24) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-24) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-24) a CDR comprising the amino acid sequence of SEQ ID NO: 90,

(d-24) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-24) a CDR comprising the amino acid sequence of SEQ ID NO: 120, and

(f-24) a CDR comprising the amino acid sequence of SEQ ID NO: 6.

6. A combination of an isolated polynucleotide comprising a nucleotide sequence that encodes a heavy chain of an isolated anti-human CD81 antibody, and an isolated polynucleotide comprising a nucleotide sequence that encodes the corresponding light chain of the isolated anti-human CD81 antibody, wherein the isolated anti-human CD81 antibody comprises:

(a-25) a CDR comprising the amino acid sequence of SEQ ID NO: 11;

(b-25) a CDR comprising the amino acid sequence of SEQ ID NO: 12;

(c-25) a CDR comprising the amino acid sequence of SEQ ID NO: 13;

(d-25) a CDR comprising the amino acid sequence of SEQ ID NO: 14;

(e-25) a CDR comprising the amino acid sequence of SEQ ID NO: 15; and

(f-25) a CDR comprising the amino acid sequence of SEQ ID NO: 16.

7. An expression vector comprising the polynucleotide of claim 1 .

8. A recombinant cell transformed with the expression vector of claim 7 .

9. A recombinant cell transformed with an expression vector comprising a polynucleotide comprising a nucleotide sequence that encodes the heavy chain of an isolated anti-human CD81 antibody, and with an expression vector comprising a polynucleotide comprising a nucleotide sequence that encodes the corresponding light chain of the anti-human CD81 antibody, wherein the anti-human CD81 antibody comprises all 6 complementarity determining regions (CDRs) described in any one of the following groups 1 to 24:

Group 1

(a-1) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-1) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-1) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-1) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-1) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-1) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 2

(a-2) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-2) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-2) a CDR comprising the amino acid sequence of SEQ ID NO: 37,

(d-2) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-2) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-2) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 3

(a-3) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-3) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-3) a CDR comprising the amino acid sequence of SEQ ID NO: 40,

(d-3) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-3) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-3) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 4

(a-4) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-4) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-4) a CDR comprising the amino acid sequence of SEQ ID NO: 43,

(d-4) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-4) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-4) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 5

(a-5) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-5) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-5) a CDR comprising the amino acid sequence of SEQ ID NO: 46,

(d-5) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-5) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-5) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 6

(a-6) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-6) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-6) a CDR comprising the amino acid sequence of SEQ ID NO: 49,

(d-6) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-6) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-6) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 7

(a-7) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-7) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-7) a CDR comprising the amino acid sequence of SEQ ID NO: 52,

(d-7) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-7) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-7) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 8

(a-8) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-8) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-8) a CDR comprising the amino acid sequence of SEQ ID NO: 43,

(d-8) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-8) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-8) a CDR comprising the amino acid sequence of SEQ ID NO: 55

Group 9

(a-9) a CDR comprising the amino acid sequence of SEQ ID NO: 60,

(b-9) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-9) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-9) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-9) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-9) a CDR comprising the amino acid sequence of SEQ ID NO: 61

Group 10

(a-10) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-10) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-10) a CDR comprising the amino acid sequence of SEQ ID NO: 66,

(d-10) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-10) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-10) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 11

(a-11) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-11) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-11) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-11) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-11) a CDR comprising the amino acid sequence of SEQ ID NO: 69, and

(f-11) a CDR comprising the amino acid sequence of SEQ ID NO: 70

Group 12

(a-12) a CDR comprising the amino acid sequence of SEQ ID NO: 60,

(b-12) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-12) a CDR comprising the amino acid sequence of SEQ ID NO: 66,

(d-12) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-12) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-12) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 13

(a-13) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-13) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-13) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-13) a CDR comprising the amino acid sequence of SEQ ID NO: 77,

(e-13) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-13) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 14

(a-14) a CDR comprising the amino acid sequence of SEQ ID NO: 80,

(b-14) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-14) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-14) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-14) a CDR comprising the amino acid sequence of SEQ ID NO: 81, and

(f-14) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 15

(a-15) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-15) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-15) a CDR comprising the amino acid sequence of SEQ ID NO: 66,

(d-15) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-15) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-15) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 16

(a-16) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-16) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-16) a CDR comprising the amino acid sequence of SEQ ID NO: 90,

(d-16) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-16) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-16) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 17

(a-17) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-17) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-17) a CDR comprising the amino acid sequence of SEQ ID NO: 52,

(d-17) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-17) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-17) a CDR comprising the amino acid sequence of SEQ ID NO: 93

Group 18

(a-18) a CDR comprising the amino acid sequence of SEQ ID NO: 98,

(b-18) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-18) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-18) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-18) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-18) a CDR comprising the amino acid sequence of SEQ ID NO: 99

Group 19

(a-19) a CDR comprising the amino acid sequence of SEQ ID NO: 60,

(b-19) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-19) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-19) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-19) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-19) a CDR comprising the amino acid sequence of SEQ ID NO: 99

Group 20

(a-20) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-20) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-20) a CDR comprising the amino acid sequence of SEQ ID NO: 90,

(d-20) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-20) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-20) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 21

(a-21) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-21) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-21) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-21) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-21) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-21) a CDR comprising the amino acid sequence of SEQ ID NO: 55

Group 22

(a-22) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-22) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-22) a CDR comprising the amino acid sequence of SEQ ID NO: 66,

(d-22) a CDR comprising the amino acid sequence of SEQ ID NO: 110,

(e-22) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-22) a CDR comprising the amino acid sequence of SEQ ID NO: 6

Group 23

(a-23) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-23) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-23) a CDR comprising the amino acid sequence of SEQ ID NO: 3,

(d-23) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-23) a CDR comprising the amino acid sequence of SEQ ID NO: 5, and

(f-23) a CDR comprising the amino acid sequence of SEQ ID NO: 115

Group 24

(a-24) a CDR comprising the amino acid sequence of SEQ ID NO: 1,

(b-24) a CDR comprising the amino acid sequence of SEQ ID NO: 2,

(c-24) a CDR comprising the amino acid sequence of SEQ ID NO: 90,

(d-24) a CDR comprising the amino acid sequence of SEQ ID NO: 4,

(e-24) a CDR comprising the amino acid sequence of SEQ ID NO: 120, and

(f-24) a CDR comprising the amino acid sequence of SEQ ID NO: 6.

10. A recombinant cell transformed with an expression vector comprising a polynucleotide comprising a nucleotide sequence that encodes the heavy chain of an isolated anti-human CD81 antibody, and with an expression vector comprising a polynucleotide comprising a nucleotide sequence that encodes the corresponding light chain of the isolated anti-human CD81 antibody, wherein the isolated anti-human CD81 antibody comprises:

(a-25) a CDR comprising the amino acid sequence of SEQ ID NO: 11;

(b-25) a CDR comprising the amino acid sequence of SEQ ID NO: 12;

(c-25) a CDR comprising the amino acid sequence of SEQ ID NO: 13;

(d-25) a CDR comprising the amino acid sequence of SEQ ID NO: 14;

(e-25) a CDR comprising the amino acid sequence of SEQ ID NO: 15; and

(f-25) a CDR comprising the amino acid sequence of SEQ ID NO: 16.

11. A method of producing an anti-human CD81 antibody, comprising culturing the recombinant cell of claim 9 , and recovering the antibody from the culture obtained.

12. A method of producing an anti-human CD81 antibody, comprising culturing the recombinant cell of claim 10 , and recovering the antibody from the culture obtained.

Assignments (1)

CHANGE OF NAME Recorded Aug 25, 2014

From: DAINIPPON SUMITOMO PHARMA CO., LTD.

To: SUMITOMO DAINIPPON PHARMA CO., LTD.

Reel/Frame 033606/0307 →